Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Preclinical in vitro and xenograft study proposing a mechanism by which an existing drug may enhance chemotherapy, without clinical efficacy data or human evidence.
V M Bekhterev Review of Psychiatry and Medical Psychology
A descriptive survey of clinician opinions and practices regarding anhedonia management, without comparative data, control groups, or validated clinical outcomes; represents clinicians' subjective views rather than empirical evidence of effectiveness.
A structured narrative review synthesizing methodological and regulatory challenges across ketamine and psilocybin trials, identifying systemic weaknesses in trial design and implementation readiness rather than reporting a primary efficacy result.
A single-centre, quasi-experimental comparison showing superiority of vilazodone over escitalopram on depression severity, but limited by single-blind design, lack of active comparator control, and modest sample size without prespecified primary endpoints.
A narrative review in a high-impact journal synthesizing expert consensus on SSRI safety in pregnancy, offering clinical guidance rather than reporting new primary data.
A well-conducted retrospective cohort study with adequate sample size and multivariate adjustment showing safety advantages (fewer memory complaints, shorter recovery time) for bifrontal ECT in adolescents, though efficacy was equivalent and cognitive assessment was limited to subjective measures.
A narrative review synthesizing preclinical animal model literature to identify biological mechanisms of depression and propose methodological improvements for drug discovery; raises questions about model validity and translational strategy rather than testing a clinical hypothesis.
A single-centre cross-sectional study identifying catatonia prevalence and predictive factors in adolescents with ASD using validated diagnostic criteria, with a modest effect size (Nagelkerke R² = 0.26) that requires confirmation in larger, prospective cohorts.